{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:39:42Z","timestamp":1784932782015,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Given the median survival of 15\u00a0months after diagnosis, novel treatment strategies are needed for glioblastoma. Beta-blockers have been demonstrated to inhibit angiogenesis and tumor cell proliferation in various cancer types. The aim of this study was to systematically review the evidence on the effect of beta-blockers on glioma growth. A systematic literature search was performed in the PubMed, Embase, Google Scholar, Web of Science, and Cochrane Central to identify all relevant studies. Preclinical studies concerning the pharmacodynamic effects of beta-blockers on glioma growth and proliferation were included, as well as clinical studies that studied the effect of beta-blockers on patient outcomes according to PRISMA guidelines. Among the 980 citations, 10 preclinical studies and 1 clinical study were included after title\/abstract and full-text screening. The following potential mechanisms were identified: reduction of glioma cell proliferation (<jats:italic>n<\/jats:italic>\u2009=\u20099), decrease of glioma cell migration (<jats:italic>n<\/jats:italic>\u2009=\u20092), increase of drug sensitivity (<jats:italic>n<\/jats:italic>\u2009=\u20091), induction of glioma cell death (<jats:italic>n<\/jats:italic>\u2009=\u20091). Beta-blockers affect glioma proliferation by inducing a brief reduction of cAMP and a temporary cell cycle arrest in vitro<jats:italic>.<\/jats:italic> Contrasting results were observed concerning glioma cell migration. The identified clinical study did not find an association between beta-blockers and survival in glioma patients. Although preclinical studies provide scarce evidence for the use of beta-blockers in glioma, they identified potential pathways for targeting glioma. Future studies are needed to clarify the effect of beta-blockers on clinical endpoints including survival outcomes in glioma patients to scrutinize the value of beta-blockers in glioma care.<\/jats:p>","DOI":"10.1007\/s10143-020-01277-4","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T15:02:30Z","timestamp":1584198150000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Beta-blockers and glioma: a systematic review of preclinical studies and clinical results"],"prefix":"10.1007","volume":"44","author":[{"given":"Ishaan Ashwini","family":"Tewarie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeky T.","family":"Senders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F. C.","family":"Hulsbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike L. D.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro-Oncology 20:iv1\u2013iv86. https:\/\/doi.org\/10.1093\/neuonc\/noy131","journal-title":"Neuro-Oncology"},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"1277_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/neuonc\/nou166","volume":"16","author":"WL Bi","year":"2014","unstructured":"Bi WL, Beroukhim R (2014) Beating the odds: extreme long-term survival with glioblastoma. Neuro-Oncology 16:1159\u20131160. https:\/\/doi.org\/10.1093\/neuonc\/nou166","journal-title":"Neuro-Oncology"},{"key":"1277_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1002\/cncr.28259","volume":"119","author":"DR Johnson","year":"2013","unstructured":"Johnson DR, Leeper HE, Uhm JH (2013) Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer 119:3489\u20133495. https:\/\/doi.org\/10.1002\/cncr.28259","journal-title":"Cancer"},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-018-2768-x","volume":"137","author":"J Rick","year":"2018","unstructured":"Rick J, Chandra A, Aghi MK (2018) Tumor treating fields: a new approach to glioblastoma therapy. J Neuro-Oncol 137:447\u2013453. https:\/\/doi.org\/10.1007\/s11060-018-2768-x","journal-title":"J Neuro-Oncol"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","volume":"13","author":"WH Frishman","year":"2011","unstructured":"Frishman WH, Saunders E (2011) Beta-adrenergic blockers. J Clin Hypertens (Greenwich) 13:649\u2013653. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00515.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","volume":"42","author":"AA Al-Majed","year":"2017","unstructured":"Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H (2017) Propranolol. Profiles Drug Subst Excip Relat Methodol 42:287\u2013338. https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.006","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.rec.2019.04.006","volume":"72","author":"E Oliver","year":"2019","unstructured":"Oliver E, Mayor F Jr, D\u2019Ocon P (2019) Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed) 72:853\u2013862. https:\/\/doi.org\/10.1016\/j.rec.2019.04.006","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"1277_CR10","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/0008-5472.Can-08-4289","volume":"69","author":"D Chakroborty","year":"2009","unstructured":"Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S (2009) Catecholamines regulate tumor angiogenesis. Cancer Res 69:3727\u20133730. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4289","journal-title":"Cancer Res"},{"key":"1277_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","volume":"53","author":"S Lamy","year":"2010","unstructured":"Lamy S, Lachambre MP, Lord-Dufour S, Beliveau R (2010) Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vasc Pharmacol 53:200\u2013208. https:\/\/doi.org\/10.1016\/j.vph.2010.08.002","journal-title":"Vasc Pharmacol"},{"key":"1277_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbi.2008.10.005","volume":"23","author":"EV Yang","year":"2009","unstructured":"Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23:267\u2013275. https:\/\/doi.org\/10.1016\/j.bbi.2008.10.005","journal-title":"Brain Behav Immun"},{"key":"1277_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/bjc.2013.205","volume":"108","author":"E Pasquier","year":"2013","unstructured":"Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M (2013) Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 108:2485\u20132494. https:\/\/doi.org\/10.1038\/bjc.2013.205","journal-title":"Br J Cancer"},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/MPA.0b013e318184f50c","volume":"38","author":"D Zhang","year":"2009","unstructured":"Zhang D, Ma Q, Shen S, Hu H (2009) Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist\u2019s anticancer effect in pancreatic cancer cell. Pancreas 38:94\u2013100. https:\/\/doi.org\/10.1097\/MPA.0b013e318184f50c","journal-title":"Pancreas"},{"key":"1277_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00432-012-1331-y","volume":"139","author":"I Kozanoglu","year":"2013","unstructured":"Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y (2013) New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J Cancer Res Clin Oncol 139:327\u2013335. https:\/\/doi.org\/10.1007\/s00432-012-1331-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18632\/oncotarget.343","volume":"2","author":"E Pasquier","year":"2011","unstructured":"Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, Andre N (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2:797\u2013809. https:\/\/doi.org\/10.18632\/oncotarget.343","journal-title":"Oncotarget"},{"key":"1277_CR17","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3892\/ol.2017.6653","volume":"14","author":"J-J He","year":"2017","unstructured":"He J-J, Zhang W-H, Liu S-L, Chen Y-F, Liao C-X, Shen Q-Q, Hu P (2017) Activation of \u03b2-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett 14:3846\u20133852. https:\/\/doi.org\/10.3892\/ol.2017.6653","journal-title":"Oncol Lett"},{"key":"1277_CR18","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1016\/0006-2952(89)90610-2","volume":"38","author":"WG Conroy","year":"1989","unstructured":"Conroy WG, Peoples RW, Isom GE (1989) Identification of functional beta-adrenergic receptors on AC glioma cells. Biochem Pharmacol 38:3175\u20133178. https:\/\/doi.org\/10.1016\/0006-2952(89)90610-2","journal-title":"Biochem Pharmacol"},{"key":"1277_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.7868\/s0026898416050074","volume":"50","author":"M Jozwiak-Bebenista","year":"2016","unstructured":"Jozwiak-Bebenista M, Wiktorowska-Owczarek A, Kowalczyk E (2016) Beta-adrenoceptor-mediated cyclic AMP signal in different types of cultured nerve cells in normoxic and hypoxic conditions. Mol Biol (Mosk) 50:838\u2013846. https:\/\/doi.org\/10.7868\/s0026898416050074","journal-title":"Mol Biol (Mosk)"},{"key":"1277_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0014-4827(75)90561-3","volume":"95","author":"A Edstrom","year":"1975","unstructured":"Edstrom A, Kanje M, Lofgren P, Walum E (1975) Drug induced alterations in morphology and level of cAMP in cultured human glioma cells. Exp Cell Res 95:359\u2013364. https:\/\/doi.org\/10.1016\/0014-4827(75)90561-3","journal-title":"Exp Cell Res"},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"1277_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.phrs.2009.05.005","volume":"60","author":"B Annabi","year":"2009","unstructured":"Annabi B, Lachambre MP, Plouffe K, Moumdjian R, B\u00e9liveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60:438\u2013445. https:\/\/doi.org\/10.1016\/j.phrs.2009.05.005","journal-title":"Pharmacol Res"},{"key":"1277_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1471-4159.1986.tb00670.x","volume":"47","author":"AJ Balmforth","year":"1986","unstructured":"Balmforth AJ, Ball SG, Freshney RI (1986) D-1 dopaminergic and \u03b2-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 47:715\u2013719","journal-title":"J Neurochem"},{"key":"1277_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo-00000563","volume":"36","author":"M Erguven","year":"2010","unstructured":"Erguven M, Yazihan N, Aktas E, Sabanci A, Chiang JLI, Oktem G, Bilir A (2010) Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36:857\u2013866. https:\/\/doi.org\/10.3892\/ijo-00000563","journal-title":"Int J Oncol"},{"key":"1277_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/bf00515554","volume":"328","author":"V Homburger","year":"1985","unstructured":"Homburger V, Gozlan H, Bouhelal R (1985) Irreversible blockade of \u03b2-adrenergic receptors with a bromoacetyl derivative of pindolol. Naunyn Schmiedeberg's Arch Pharmacol 328:279\u2013287. https:\/\/doi.org\/10.1007\/bf00515554","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1277_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jcp.1041210318","volume":"121","author":"V Homburger","year":"1984","unstructured":"Homburger V, Pantaloni C, Lucas M (1984) \u03b2 Adrenergic receptor repopulation of C6 glioma cells after irreversible blockade and down regulation. J Cell Physiol 121:589\u2013597. https:\/\/doi.org\/10.1002\/jcp.1041210318","journal-title":"J Cell Physiol"},{"key":"1277_CR27","doi-asserted-by":"publisher","first-page":"1850025","DOI":"10.1142\/S1793545818500256","volume":"11","author":"O Pavlova","year":"2018","unstructured":"Pavlova O, Shirokov A, Fomin A, Navolokin N, Terskov A, Khorovodov A, Namykin A, Pavlov A, Tuchin V, Semyachkina-Glushkovskaya O (2018) Optical in vivo and ex vivo imaging of glioma cells migration via the cerebral vessels: prospective clinical application of the beta2-adrenoreceptors blockade for glioma treatment. J Innov Opt Health Sci 11:1850025. https:\/\/doi.org\/10.1142\/S1793545818500256","journal-title":"J Innov Opt Health Sci"},{"key":"1277_CR28","first-page":"659","volume":"57","author":"P Sokolowska","year":"2005","unstructured":"Sokolowska P (2005) Constitutive activity of beta-adrenergic receptors in C6 Glioma cells. Pharmacol Rep 57:659\u2013663","journal-title":"Pharmacol Rep"},{"key":"1277_CR29","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1073\/pnas.76.12.6401","volume":"76","author":"WL Terasaki","year":"1979","unstructured":"Terasaki WL, Linden J, Brooker G (1979) Quantitative relationship between beta-adrenergic receptor number and physiologic responses as studied with a long-lasting beta-adrenergic antagonist. Proc Natl Acad Sci U S A 76:6401\u20136405","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1277_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/07357907.2018.1544639","volume":"36","author":"MD Johansen","year":"2018","unstructured":"Johansen MD, Urup T, Holst CB, Christensen IJ, Grunnet K, Lassen U, Friis S, Poulsen HS (2018) Outcome of bevacizumab therapy in patients with recurrent glioblastoma treated with angiotensin system inhibitors. Cancer Investig 36:512\u2013519. https:\/\/doi.org\/10.1080\/07357907.2018.1544639","journal-title":"Cancer Investig"},{"key":"1277_CR31","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1523\/JNEUROSCI.21-19-07724.2001","volume":"21","author":"M Asahi","year":"2001","unstructured":"Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724\u20137732","journal-title":"J Neurosci"},{"key":"1277_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/3-211-30714-1_29","volume":"96","author":"Y Shigemori","year":"2006","unstructured":"Shigemori Y, Katayama Y, Mori T, Maeda T, Kawamata T (2006) Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl 96:130\u2013133","journal-title":"Acta Neurochir Suppl"},{"key":"1277_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/BF01753836","volume":"12","author":"T Abe","year":"1994","unstructured":"Abe T, Mori T, Kohno K, Seiki M, Hayakawa T, Welgus HG, Hori S, Kuwano M (1994) Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells. Clin Exp Metastasis 12:296\u2013304","journal-title":"Clin Exp Metastasis"},{"key":"1277_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00300442","volume":"28","author":"T Nakagawa","year":"1996","unstructured":"Nakagawa T, Kubota T, Kabuto M, Fujimoto N, Okada Y (1996) Secretion of matrix metalloproteinase-2 (72 kD gelatinase\/type IV collagenase = gelatinase a) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. J Neuro-Oncol 28:13\u201324","journal-title":"J Neuro-Oncol"},{"key":"1277_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.biolcel.2004.05.002","volume":"96","author":"Y Audic","year":"2004","unstructured":"Audic Y, Hartley RS (2004) Post-transcriptional regulation in cancer. Biol Cell 96:479\u2013498. https:\/\/doi.org\/10.1016\/j.biolcel.2004.05.002","journal-title":"Biol Cell"},{"key":"1277_CR36","first-page":"881","volume":"141","author":"J Dalmau","year":"1992","unstructured":"Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB (1992) The expression of the Hu (paraneoplastic encephalomyelitis\/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 141:881\u2013886","journal-title":"Am J Pathol"},{"key":"1277_CR37","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.febslet.2008.03.004","volume":"582","author":"T Glisovic","year":"2008","unstructured":"Glisovic T, Bachorik JL, Yong J, Dreyfuss G (2008) RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 582:1977\u20131986. https:\/\/doi.org\/10.1016\/j.febslet.2008.03.004","journal-title":"FEBS Lett"},{"key":"1277_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ana.410390520","volume":"39","author":"PH King","year":"1996","unstructured":"King PH, Dropcho EJ (1996) Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma. Ann Neurol 39:679\u2013681. https:\/\/doi.org\/10.1002\/ana.410390520","journal-title":"Ann Neurol"},{"key":"1277_CR39","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.1038\/s41598-017-09040-4","volume":"7","author":"SK Lee","year":"2017","unstructured":"Lee SK, Park KK, Kim HJ, Park J, Son SH, Kim KR, Chung WY (2017) Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep 7:9610\u20139613. https:\/\/doi.org\/10.1038\/s41598-017-09040-4","journal-title":"Sci Rep"},{"key":"1277_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.trsl.2016.04.002","volume":"175","author":"K Mitsunari","year":"2016","unstructured":"Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T, Sakai H (2016) Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer. Transl Res 175:116\u2013128. https:\/\/doi.org\/10.1016\/j.trsl.2016.04.002","journal-title":"Transl Res"},{"key":"1277_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4161\/rna.3.3.3373","volume":"3","author":"P Sanchez-Diaz","year":"2006","unstructured":"Sanchez-Diaz P, Penalva LO (2006) Post-transcription meets post-genomic: the saga of RNA binding proteins in a new era. RNA Biol 3:101\u2013109","journal-title":"RNA Biol"},{"key":"1277_CR42","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1124\/jpet.102.045260","volume":"304","author":"H Dai","year":"2003","unstructured":"Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085\u20131092. https:\/\/doi.org\/10.1124\/jpet.102.045260","journal-title":"J Pharmacol Exp Ther"},{"key":"1277_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3171\/jns.1991.74.3.0460","volume":"74","author":"M Tsuyoshi","year":"1991","unstructured":"Tsuyoshi M, Eiichi T, Keizo K, Hideki S, Katsuya M (1991) Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74:460\u2013466. https:\/\/doi.org\/10.3171\/jns.1991.74.3.0460","journal-title":"J Neurosurg"},{"key":"1277_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15:535\u2013541. https:\/\/doi.org\/10.1023\/B:CACO.0000036152.58271.5e","journal-title":"Cancer Causes Control"},{"key":"1277_CR45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1940-6207.capr-11-0450","volume":"5","author":"G Nkontchou","year":"2012","unstructured":"Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M (2012) Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 5:1007\u20131014. https:\/\/doi.org\/10.1158\/1940-6207.capr-11-0450","journal-title":"Cancer Prev Res (Phila)"},{"key":"1277_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clbc.2015.07.001","volume":"15","author":"WK Childers","year":"2015","unstructured":"Childers WK, Hollenbeak CS, Cheriyath P (2015) Beta-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer 15:426\u2013431. https:\/\/doi.org\/10.1016\/j.clbc.2015.07.001","journal-title":"Clin Breast Cancer"},{"key":"1277_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc1121","volume":"3","author":"JS Rao","year":"2003","unstructured":"Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489\u2013501. https:\/\/doi.org\/10.1038\/nrc1121","journal-title":"Nat Rev Cancer"},{"key":"1277_CR48","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1101\/gad.1990410","volume":"24","author":"A Beliveau","year":"2010","unstructured":"Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, Muschler J, Bissell MJ (2010) Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev 24:2800\u20132811. https:\/\/doi.org\/10.1101\/gad.1990410","journal-title":"Genes Dev"},{"key":"1277_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/10409230290771546","volume":"37","author":"PE Van den Steen","year":"2002","unstructured":"Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37:375\u2013536. https:\/\/doi.org\/10.1080\/10409230290771546","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"1277_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11060-011-0565-x","volume":"104","author":"R Henriksson","year":"2011","unstructured":"Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neuro-Oncol 104:639\u2013646. https:\/\/doi.org\/10.1007\/s11060-011-0565-x","journal-title":"J Neuro-Oncol"},{"key":"1277_CR51","doi-asserted-by":"crossref","unstructured":"Bhattacharyya GS, Ranade A, Malhotra H, Babu KG, Shahid T, Parikh PM, Bascomb NF, Chanda AS (2014) Continuous metronomic temozolamide with propranolol and etodolac in recurrent globlastoma: a pilot study. J Clin Oncol 32","DOI":"10.1200\/jco.2014.32.15_suppl.e13005"},{"key":"1277_CR52","doi-asserted-by":"crossref","unstructured":"Shahid T, Bhattacharyya GS, Malhotra H, Govindbabu KS, Parikh PM, Ranade A, Biswas G, Bondarde SA, Chanda A, Bascomb NF (2015) Continuous low dose temozolamide with or without VT-122 in glioblastoma. J Clin Oncol 33","DOI":"10.1200\/jco.2015.33.15_suppl.e13010"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-020-01277-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-020-01277-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-020-01277-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T13:05:21Z","timestamp":1617973521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-020-01277-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1007\/s10143-020-01277-4","relation":{},"ISSN":["0344-5607","1437-2320"],"issn-type":[{"value":"0344-5607","type":"print"},{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}